XLO
What one share of Xilio Therapeutics holds
Pharmaceutical Preparations
We are a clinical-stage biotechnology company discovering and developing masked immuno-oncology, or I-O, therapies with the goal of significantly improving outcomes for people living with cancer. Leveraging our clinically-validated masking technology and capabilities, we are developing I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents.
Xilio Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $4.50 |
|---|---|
| Profit | −$1.53 |
| Capex (buildings and equipment) | $0.05 |
| Free cash flow | −$4.30 |
| Cash and investments | $20.67 |
| Book value | $10.98 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$105.42 | $4.18 | −$73.08 | — | −$120.72 |
| 2021 | — | −$13.52 | $0.20 | −$14.60 | — | — |
| 2022 | — | −$3.22 | $0.07 | −$2.83 | — | $3.85 |
| 2023 | — | −$2.78 | $0.02 | −$2.51 | — | $1.33 |
| 2024 | $1.66 | −$15.24 | $0.01 | −$4.82 | — | $5.38 |
| 2025 | $5.24 | −$4.19 | $0.06 | −$0.66 | — | $7.79 |